Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer

Next Previous
Trial Profile

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Guadecitabine (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 16 Mar 2023 Results assessing safety and efficacy of guadecitabine plus atezolizumab in metastatic urothelial carcinoma, published in the Clinical Cancer Research.
    • 10 Apr 2021 Primary endpoint of Objective Response Rate has not been met according to results presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 10 Apr 2021 Status changed from active, no longer recruiting to discontinued as per it was determined that the trial would not meet its primary endpoint and it closed early according to results presented at the 112th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top